肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
登录/注册
VIP特权

文章目录

肿瘤靶向细菌被设计用来对抗癌症

Tumour-targeting bacteria engineered to fight cancer

原文发布日期:2018-11-07

DOI: 10.1038/s41568-018-0070-z

类型: Review Article

开放获取: 否

英文摘要:

摘要翻译: 

原文链接:

文章:

肿瘤靶向细菌被设计用来对抗癌症

Tumour-targeting bacteria engineered to fight cancer

原文发布日期:2018-11-07

DOI: 10.1038/s41568-018-0070-z

类型: Review Article

开放获取: 否

 

英文摘要:

Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, most late-stage cancers are either insensitive to the therapies to begin with or develop resistance later. Therapy with live tumour-targeting bacteria provides a unique option to meet these challenges. Compared with most other therapeutics, the effectiveness of tumour-targeting bacteria is not directly affected by the ‘genetic makeup’ of a tumour. Bacteria initiate their direct antitumour effects from deep within the tumour, followed by innate and adaptive antitumour immune responses. As microscopic ‘robotic factories’, bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents on the basis of clinical needs. Therapeutic approaches using live tumour-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumour regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumour-targeting bacteria, including a discussion of the regulatory issues.

 

摘要翻译: 

靶向治疗和免疫疗法的最新进展再次燃起了人们对多种癌症类型可能迎来治愈的希望。然而,大多数晚期癌症要么从一开始就对治疗不敏感,要么随后产生耐药性。利用靶向肿瘤的活菌疗法为应对这些挑战提供了独特选择。与大多数其他治疗方法相比,靶向肿瘤细菌的疗效不受肿瘤"基因构成"的直接影响。细菌从肿瘤深部启动直接抗肿瘤效应,继而引发先天性和适应性抗肿瘤免疫反应。作为微型"机器人工厂",细菌载体可依据简单遗传法则或复杂合成生物工程原理进行重编程,根据临床需求生产并递送抗癌制剂。这种靶向肿瘤的活菌疗法既可单独实施,也可与其他抗癌疗法联合应用以获得更佳临床效果。本综述将系统阐述该疗法的潜在优势与挑战,探讨活菌选择性诱导肿瘤消退的机制,并通过案例说明细菌工程化改造以提升安全性与有效性的多种路径。最后,我们将结合靶向菌肿瘤临床试验的经验与见解,对相关监管问题进行探讨。

 

原文链接:

Tumour-targeting bacteria engineered to fight cancer

相关文章

文章:肿瘤抗原优先来源于黑色素瘤和非小细胞肺癌中未突变的基因组序列
文章:年龄相关的烟酰胺腺嘌呤二核苷酸下降驱动CAR-T细胞衰竭
文章:MCSP+转移创始细胞在人类黑色素瘤转移定植早期激活免疫抑制
文章:脂质纳米颗粒递送合成抗原使实体瘤对car介导的细胞毒性敏感
文章:食管癌新辅助治疗中的进化和免疫微环境动力学
文章:CHD1缺失重编程srebp2驱动的胆固醇合成,在spop突变的前列腺肿瘤中促进雄激素响应性生长和去势抵抗
文章:对TIL细胞治疗无反应的转移性非小细胞肺癌患者的T细胞和新抗原保留受损的时间序列分析
文章:策展的癌细胞图谱提供了单细胞分辨率的肿瘤的全面表征
文章:以人群为基础的胶质瘤分子景观分析在青少年和年轻人揭示胶质瘤形成的见解
文章:肿瘤细胞上的PILRα与T细胞表面蛋白CD99相互作用抑制抗肿瘤免疫

……